In this project two high-risk DLBCL subtypes with poor outcomes: those with biallelic TP53 inactivation and those arising from CLL transformation are investigated. It uses a multi-omic approach, including genomic, transcriptomic, and spatial analyses, to uncover drivers of transformation and resistance. Potential druggable targets like XPO1, RANBP2, and MCL1 have been identified through CRISPR screening and are being tested in lymphoma models. The goal is to inform biologically-guided clinical trials to improve treatment for high-risk DLBCL.
PRINCIPAL INVESTIGATOR
Department of Hematology, Oncology and Tumorimmunology
Charité Universitätsmedizin Berlin
Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin
German CLL Study Group
Department I of Internal Medicine
University Hospital of Cologne
Kerpener Straße 62
50937 Cologne
Project Interactions
-
A01
Deciphering the role of oncogenic BTK mutations in DLBCL
Prof. Dr. med. Hans Christian Reinhardt, Dr. med. Sebastian Scheich -
A02
Targeting UBA6 signaling in B cell lymphoma
Prof. Dr. med. Thomas Oellerich, Dr. med. Ruth Fluemann -
A03
LUBAC and its enzymatic activities in the development and therapy of ABC-diffuse large B-cell lymphoma
Prof. Dr. rer. nat. Henning Walczak, Dr. rer. nat. Gianmaria Liccardi -
A04
Role of CASP8/cFLIP dimer in controlling lymphomagenesis
Prof. Dr. rer. nat. Hamid Kashkar, Dr. rer. nat. Alessandro Annibaldi -
B01
Dissecting the role of tyrosine kinases as key regulators and therapeutic targets in the microenvironment of chronic lymphocytic leukemia
Prof. Dr. med. Michael Hallek, Dr. med. Laura Beckmann -
B02
Temporal and spatial elucidation of NF- κB signaling in B cell lymphomagenesis
Prof. Dr. med. Christian Pallasch, Prof. Dr. rer. nat. Manolis Pasparakis -
B03
Targeting fumarate hydratase as metabolic gateway to ferroptosis sensitization
Prof. Dr. rer. nat. Silvia von Karstedt, Prof. Dr. rer. nat. Christian Frezza, Prof. Dr. med. Hans Christian Reinhardt -
B05
Combining TME modulating targeted therapies with new CAR-T cell strategies to improve CAR-T cell response in B cell lymphomas
Dr. rer. nat. Markus Chmielewski, Prof. Dr. med. Dr. nat. med. Roland Ullrich -
C01
The role of NLRC5 and additional genetic and microenvironmental factors in the pathogenesis and immunotherapeutic targeting of classic Hodgkin lymphoma
Prof. Dr. rer. nat. Ralf Küppers, Dr. rer. nat. Maria Cartolano -
C02
Functional Elucidation of highrisk Mantle Cell Lymphoma and CAR-T cell Therapy Resistance
Dr. med. Ron Jachimowicz, Dr. med. Stefan Alig, Prof. Dr. med. Thomas Oellerich -
C04
Modeling the clonal evolution of high-risk CLL
Prof. Dr. rer. nat. Martin Peifer, Dr. med. Kirsten Fischer -
Z01
Central administration project
Prof. Dr. med. Michael Hallek -
Z02
Service project: Multiparametric analysis of lymphoma cells and their microenvironment
Prof. Dr. med. Thomas Oellerich, Dr. med. Lukas Frenzel, Prof. Dr. med. Dr. rer. nat. Michal Schweiger, Dr. rer. nat. Marie-Christine Albert, Dr. med. Lena Katharina Hieggelke -
Z03
Information infrastructure project (INF): Bioinformatics and Data management
Prof. Dr. rer. nat. Martin Peifer, Dr. rer. nat. Monica Valencia-Schneider, Dr. rer. nat. Nima Abedpour, Dr. rer. nat. Rahil Gholamipoorfard